Halozyme Therapeutics, Inc. Income Statement

1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2009 Dec2010 Dec2011 Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 13.67M13.62M56.09M42.33M54.80M75.33M135.06M146.69M316.61M151.86M195.99M267.59M443.31M660.12M829.25M1015.32M
Cost of Revenue 0.31M0.99M0.26M1.09M6.25M22.73M29.25M33.21M31.15M10.14M45.55M43.37M81.41M139.30M192.36M159.42M
Gross Profit 13.36M12.64M55.83M41.23M48.55M52.60M105.81M113.48M285.46M141.73M150.45M224.23M361.90M520.81M636.89M855.91M
Operating items
Amortization - Intangibles 43.15M73.77M71.05M
Research & Development 56.61M51.77M57.56M70.04M96.64M79.70M93.24M150.84M150.64M150.25M140.80M34.24M35.67M66.61M76.36M79.05M
Selling, General & Administrative 15.20M15.12M18.10M24.81M32.35M35.94M40.03M45.85M53.82M60.80M77.25M45.74M50.32M143.53M149.18M154.34M
Other Operating Expenses 0.31M0.99M0.26M1.09M6.25M22.73M29.25M33.21M31.15M10.14M45.55M43.37M81.41M182.45M266.13M230.47M
Operating Expenses 72.13M67.88M75.93M95.95M135.23M138.37M162.51M229.90M235.61M221.19M263.60M123.34M167.41M392.58M491.68M463.85M
Operating Income -58.46M-54.26M-19.84M-53.62M-80.43M-63.04M-27.45M-83.21M81.00M-69.33M-67.61M144.25M275.90M267.53M337.57M551.48M
EBIT -58.46M-54.26M-19.84M-53.62M-80.43M-63.04M-27.45M-83.21M81.00M-69.33M-67.61M144.25M275.90M267.53M337.57M551.48M
Non-operating items
Interest & Investment Income 0.10M0.07M0.07M0.23M0.24M0.42M1.33M
Other Non Operating Income 0.10M1.02M0.07M0.42M1.33M2.59M7.58M6.99M5.42M1.10M1.05M16.32M23.75M
Non Operating Income 0.10M1.02M0.07M0.42M1.33M2.59M7.58M6.99M5.42M1.10M1.05M16.32M23.75M
Net income details
EBT -58.36M-53.24M-19.77M-53.55M-83.48M-68.38M-32.23M-101.86M61.61M-79.79M-72.25M129.30M248.52M248.92M348.33M557.13M
Tax Provisions 1.16M-1.36M0.54M-0.01M0.22M-154.19M46.79M66.73M113.04M
Profit After Tax -58.36M-53.24M-19.77M-53.55M-83.48M-68.38M-32.23M-103.02M62.97M-80.33M-72.24M129.09M402.71M202.13M281.59M444.09M
Income from Continuing Operations -58.36M-53.24M-19.77M-53.55M-83.48M-68.38M-32.23M-103.02M62.97M-80.33M-72.24M129.09M402.71M202.13M281.59M444.09M
Consolidated Net Income -58.36M-53.24M-19.77M-53.55M-83.48M-68.38M-32.23M-103.02M62.97M-80.33M-72.24M129.09M402.71M202.13M281.59M444.09M
Income towards Parent Company -58.36M-53.24M-19.77M-53.55M-83.48M-68.38M-32.23M-103.02M62.97M-80.33M-72.24M129.09M402.71M202.13M281.59M444.09M
Net Income towards Common Stockholders -58.36M-53.24M-19.77M-53.55M-83.48M-68.38M-32.23M-103.02M62.97M-80.33M-72.24M129.09M402.71M202.13M281.59M444.09M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M0.00M-0.00M-0.00M0.00M0.00M0.00M0.00M0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M0.00M-0.00M-0.00M0.00M0.00M0.00M0.00M0.00M
Shares Outstanding (Weighted Average) 91.65M100.43M103.69M112.71M114.03M125.39M128.01M129.49M142.36M144.56M146.54M135.18M140.79M135.21M132.10M127.23M
Shares Outstanding (Diluted Average) 126.70M127.96M139.07M143.60M144.33M141.46M146.80M140.61M134.20M129.42M
EBITDA -58.46M-54.26M-19.84M-53.62M-80.43M-63.04M-27.45M-83.21M81.00M-69.33M-67.61M144.25M275.90M267.53M337.57M551.48M
Tax Rate 0.02%0.17%18.80%19.16%20.29%